Prevalence, Incidence, and Metabolic Characteristics of Young Adults with Type 2 Diabetes Mellitus in South Korea (2010–2020)
Diabetes & Metabolism Journal,
Год журнала:
2025,
Номер
49(2), С. 172 - 182
Опубликована: Март 1, 2025
Background:
This
study
aimed
to
examine
trends
in
the
prevalence,
incidence,
metabolic
characteristics,
and
management
of
type
2
diabetes
mellitus
(T2DM)
among
young
adults
South
Korea.Methods:
Young
with
T2DM
were
defined
as
individuals
aged
19
39
years
who
met
diagnostic
criteria
for
T2DM.
Data
from
Korean
National
Health
Insurance
Service-Customized
Database
(2010–2020,
<i>n</i>=225,497–372,726)
analyzed
evaluate
profiles,
comorbidities,
antidiabetic
drug
prescription.
Additional
analyses
performed
using
Korea
Nutrition
Examination
Survey.Results:
The
prevalence
significantly
increased
1.02%
2010
2.02%
2020
(<i>P</i><0.001),
corresponding
372,726
patients
2020.
Over
same
period,
incidence
rate
remained
stable
within
range
0.36%
0.45%.
Prediabetes
steadily
15.53%
20.92%,
affecting
3.87
million
proportion
obese
also
increased,
67.8%
having
a
body
mass
index
(BMI)
≥25
kg/m²
31.6%
BMI
≥30
hypertension,
dyslipidemia,
fatty
liver
disease
reaching
34.2%,
79.8%,
78.9%,
respectively,
Although
overall
pharmacological
treatment
low,
prescription
medications
weight-reducing
properties
over
period.Conclusion:
nearly
doubled
past
decade.
strong
association
obesity
comorbidities
emphasizes
urgent
need
targeted
prevention
strategies
tailored
this
population.
Язык: Английский
Escalating Lipid Therapy After Achieving LDL-C <70 mg/dL With Moderate-Intensity Statins in High-Risk Patients
Korean Circulation Journal,
Год журнала:
2024,
Номер
55(5), С. 426 - 426
Опубликована: Дек. 9, 2024
Guidelines
recommend
target
levels
of
low-density
lipoprotein
cholesterol
(LDL-C)
and
intensive
lipid-lowering
therapy
(LLT)
in
high-risk
patients.
However,
the
value
escalating
LLT
when
LDL-C
targets
are
achieved
with
moderate-intensity
statins
is
unknown.
We
aimed
to
evaluate
benefits
escalation
this
population.
In
retrospective
propensity
score-matched
study,
we
screened
data
from
two
university
hospitals
between
2006
2021.
Of
54,069
patients
atherosclerotic
cardiovascular
disease
(ASCVD),
3,205
who
<70
mg/dL
were
included.
After
1:3
matching,
1,315
(339
976
without)
ultimately
examined.
The
primary
outcomes
major
adverse
cerebrovascular
events
(MACCE)1
(cardiovascular
death,
nonfatal
myocardial
infarction,
ischemic
stroke)
all-cause
death.
During
a
median
follow-up
5.7
years,
MACCE1
rate
was
not
significantly
lower
group
than
non-escalation
(9.8
14.3/1,000
person-years,
respectively;
hazard
ratio
[HR],
0.68;
95%
confidence
interval
[CI],
0.43-1.09;
p=0.11).
Kaplan-Meier
curves
showed
similar
results
(log-rank
risk
death
did
differ
groups.
MACCE2
rate,
which
additionally
includes
coronary/peripheral
revascularization,
(24.5
35.4/1,000
HR,
0.70;
CI,
0.52-0.94;
p=0.017).
hard
ASCVD
achieving
statins.
it
had
benefit
reducing
revascularization
rates
Язык: Английский